

CONFIDENTIAL: CAMP PRIMARY OUTCOME RESULTS

Table 1 (supplement). Baseline Demographic and Clinical Characteristics of Randomized Patients

	<i>Olanzapine</i>						<i>Quetiapine</i>						<i>Risperidone</i>					
	<i>Total (N=74)</i>		<i>Switch (N=38)</i>		<i>Stay (N=36)</i>		<i>Total (N=60)</i>		<i>Switch (N=30)</i>		<i>Stay (N=30)</i>		<i>Total (N=81)</i>		<i>Switch (N=41)</i>		<i>Stay (N=40)</i>	
Demographic characteristics	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Age - yr	42	11.8	41	12.8	42	10.8	42	10.0	41	10.6	43	9.4	40	11.4	39	11.5	41	11.3
Education - yr	12	2.5	12	2.5	12	2.6	12	2.2	12	1.4	13	2.8	13	2.6	13	2.6	13	2.6
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Sex																		
Male	49	66.2	25	65.8	24	66.7	32	53.3	14	46.7	18	60.0	56	69.1	29	70.7	27	67.5
Female	25	33.8	13	34.2	12	33.3	28	46.7	16	53.3	12	40.0	25	30.9	12	29.3	13	32.5
Race																		
White	42	56.8	20	52.6	22	61.1	32	53.3	18	60.0	14	46.7	49	60.5	27	65.9	22	55.0
Black	28	37.8	16	42.1	12	33.3	24	40.0	10	33.3	14	46.7	28	34.6	13	31.7	15	37.5
Other	2	2.7	1	2.6	1	2.8	4	6.7	2	6.7	2	6.7	4	4.9	1	2.4	3	7.5
Spanish, Hispanic or Latino ethnicity	12	16.2	4	10.5	8	22.2	9	15.0	5	16.7	4	13.3	18	22.2	10	24.4	8	20.0
High school education or above	52	70.3	28	73.7	24	66.7	47	78.3	22	73.3	25	83.3	67	82.7	33	80.5	34	85.0
Marital Status																		
Married	4	5.4	4	10.5			7	11.7	3	10.0	4	13.3	5	6.2	2	4.9	3	7.5
Previously Married	17	23.0	9	23.7	8	22.2	26	43.3	11	36.7	15	50.0	23	28.4	13	31.7	10	25.0
Never Married	53	71.6	25	65.8	28	77.8	27	45.0	16	53.3	11	36.7	53	65.4	26	63.4	27	67.5
Living Situation																		
Independent/non-structured	59	79.7	31	81.6	28	77.8	53	88.3	27	90.0	26	86.7	65	80.2	32	78.0	33	82.5
Other	15	20.3	7	18.4	8	22.2	7	11.7	3	10.0	4	13.3	16	19.8	9	22.0	7	17.5
Clinical characteristics	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Non-HDL Cholesterol - mg/dL	181	35.8	180	38.9	181	32.6	173	33.5	165	24.9	181	39.1	165	27.9	163	27.1	168	28.7
HDL Cholesterol - mg/dL	44	10.2	45	10.8	43	9.6	44	11.1	43	13.1	45	8.9	44	12.6	46	13.5	43	11.6
Weight - kg	96	16.2	101	16.0	92	15.2	110	22.3	110	21.4	109	23.6	105	21.4	103	23.8	107	18.9
Body Mass Index	33	4.9	34	5.4	32	3.9	37	7.8	37	7.6	37	8.2	35	6.1	35	5.9	36	6.3
Total Cholesterol - mg/dL	225	37.2	224	39.9	225	34.6	217	31.3	208	24.1	225	35.5	210	29.6	208	31.2	211	28.1
LDL Cholesterol - mg/dL	149	31.6	148	29.7	151	33.7	138	25.8	133	19.7	145	30.3	132	23.5	132	23.2	132	24.2
Triglycerides - mg/dL	161	79.2	169	94.0	153	60.2	180	106.5	161	88.8	199	120.2	166	97.2	156	85.4	177	108.0
TG/HDL ratio	4	2.5	4	2.8	4	2.2	5	3.3	4	3.2	5	3.5	4	3.4	4	3.0	5	3.8
HbA1c - %	6	0.4	6	0.4	6	0.3	6	0.5	6	0.6	5	0.4	5	0.5	5	0.4	5	0.5
Fasting glucose - mg/dL	96	11.5	95	11.8	97	11.1	96	11.3	98	10.8	95	11.7	97	11.6	96	9.6	98	13.3

CONFIDENTIAL: CAMP PRIMARY OUTCOME RESULTS

Table 1 (supplement). Baseline Demographic and Clinical Characteristics of Randomized Patients

	<i>Olanzapine</i>						<i>Quetiapine</i>						<i>Risperidone</i>					
	<i>Total (N=74)</i>		<i>Switch (N=38)</i>		<i>Stay (N=36)</i>		<i>Total (N=60)</i>		<i>Switch (N=30)</i>		<i>Stay (N=30)</i>		<i>Total (N=81)</i>		<i>Switch (N=41)</i>		<i>Stay (N=40)</i>	
2-hour glucose - mg/dL	132	37.9	128	30.8	135	44.3	127	43.2	128	42.6	125	44.5	122	42.3	123	40.7	121	44.3
Fasting insulin - mU/L	15	12.4	15	9.8	15	14.9	16	13.3	19	13.7	14	12.7	17	13.5	14	8.5	21	16.9
2-hour insulin - mU/L	103	139.4	111	142.9	96	137.2	79	86.1	88	98.4	70	72.4	78	71.6	77	81.2	79	61.4
C-reactive protein	6	7.4	8	9.3	5	4.1	8	9.9	9	10.3	8	9.5	6	8.3	4	5.6	7	10.3
PANSS Total	67	14.9	68	14.1	66	15.8	67	15.0	64	11.9	70	17.0	64	18.5	63	19.9	66	17.0
CGI-Severity score	4	0.8	4	0.8	4	0.8	4	0.9	4	0.9	4	1.0	4	0.9	3	1.0	4	0.9
SF-12 mntl health score	48	10.6	47	10.7	49	10.4	40	11.1	40	11.3	41	11.0	46	11.6	44	11.6	48	11.2
SF-12 phys health score	47	10.0	48	10.7	46	9.3	43	10.9	44	9.8	42	11.9	46	9.9	47	9.2	45	10.6
IWQoL Total	60	28.0	63	32.4	57	22.7	73	30.0	75	28.9	71	31.5	65	27.8	60	23.8	70	30.9